Global biotechnology company Immunospot cites using B cells isolated from HemaCare-sourced peripheral blood mononuclear cells (PBMC)  for their studies on post-cryopreservation functionality.
Expectations are high that emerging field of cell therapy will be able to deliver breakthrough treatments or cures for many diseases, including cancer. One of the most powerful facets of this new medical field is the concept of immunotherapy--using the body’s own immune cells to specifically target disease. Immune cell function is at the heart of this concept, so keeping immune cells fully operational is crucially important. In this recent study published in the journal Cells, biopharmaceutical scientists aim to investigate B cell functionality following cryopreservation.